449 related articles for article (PubMed ID: 30938848)
1. Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
Mondello P; Mian M
Hematol Oncol; 2019 Oct; 37(4):333-344. PubMed ID: 30938848
[TBL] [Abstract][Full Text] [Related]
2. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S; Barta SK
Am J Hematol; 2021 May; 96(5):617-629. PubMed ID: 33661537
[TBL] [Abstract][Full Text] [Related]
3. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.
Balasubramanian S; Wang S; Major C; Hodkinson B; Schaffer M; Sehn LH; Johnson P; Zinzani PL; Carey J; Shreeve SM; Sun S; Gerecitano J; Vermeulen J; Staudt LM; Wilson W
Br J Haematol; 2021 Jul; 194(1):83-91. PubMed ID: 33942292
[TBL] [Abstract][Full Text] [Related]
6. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
7. Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy.
Sha C; Barrans S; Cucco F; Bentley MA; Care MA; Cummin T; Kennedy H; Thompson JS; Uddin R; Worrillow L; Chalkley R; van Hoppe M; Ahmed S; Maishman T; Caddy J; Schuh A; Mamot C; Burton C; Tooze R; Davies A; Du MQ; Johnson PWM; Westhead DR
J Clin Oncol; 2019 Jan; 37(3):202-212. PubMed ID: 30523719
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
[TBL] [Abstract][Full Text] [Related]
9. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity.
Sehn LH; Gascoyne RD
Blood; 2015 Jan; 125(1):22-32. PubMed ID: 25499448
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
11. Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma.
Roschewski M; Dunleavy K; Wilson WH
Leuk Lymphoma; 2014 Nov; 55(11):2428-37. PubMed ID: 24438195
[TBL] [Abstract][Full Text] [Related]
12. [Current therapeutic strategies for diffuse large B‑cell lymphoma].
Pfreundschuh M
Internist (Berl); 2016 Mar; 57(3):214-21. PubMed ID: 26847364
[TBL] [Abstract][Full Text] [Related]
13. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
14. Maintenance therapy in diffuse large B-cell lymphoma.
Michallet AS; Lebras L; Coiffier B
Curr Opin Oncol; 2012 Sep; 24(5):461-5. PubMed ID: 22759738
[TBL] [Abstract][Full Text] [Related]
15. Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
Beygi S; Sadashiv S; Reilly JB; Khan C; Lister J
Leuk Lymphoma; 2018 Dec; 59(12):2847-2861. PubMed ID: 29616868
[TBL] [Abstract][Full Text] [Related]
16. Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.
Gisselbrecht C
Br J Haematol; 2008 Dec; 143(5):607-21. PubMed ID: 18950460
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
19. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]